J. Goldman & Co LP Takes Position in Immix Biopharma, Inc. $IMMX

J. Goldman & Co LP purchased a new position in Immix Biopharma, Inc. (NASDAQ:IMMX) during the second quarter, Holdings Channel.com reports. The institutional investor purchased 198,732 shares of the company’s stock, valued at approximately $2,049,000.

Several other large investors have also recently made changes to their positions in IMMX. Allworth Financial LP acquired a new position in Immix Biopharma in the 4th quarter valued at $30,000. Legal & General Group Plc purchased a new stake in shares of Immix Biopharma during the second quarter worth $41,000. Mathes Company Inc. purchased a new stake in shares of Immix Biopharma during the fourth quarter worth $56,000. Compass Financial Management LLC acquired a new stake in shares of Immix Biopharma in the second quarter valued at about $56,000. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Immix Biopharma in the fourth quarter worth about $67,000. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on IMMX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research note on Friday, July 17th. Morgan Stanley dropped their price target on Immix Biopharma from $20.00 to $19.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Citigroup reiterated a “market outperform” rating on shares of Immix Biopharma in a research report on Friday, August 14th. Bank of America started coverage on Immix Biopharma in a research note on Thursday, June 18th. They set a “buy” rating and a $27.00 price objective on the stock. Finally, Needham & Company LLC started coverage on Immix Biopharma in a research note on Wednesday, July 22nd. They issued a “buy” rating and a $21.00 target price for the company. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $21.29.

Immix Biopharma Stock Performance

IMMX stock opened at $14.47 on Wednesday. Immix Biopharma, Inc. has a one year low of $1.94 and a one year high of $15.10. The firm has a market cap of $1.04 billion, a PE ratio of -16.44 and a beta of 0.11. The firm’s 50 day moving average price is $10.30 and its 200-day moving average price is $9.40.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Equities research analysts predict that Immix Biopharma, Inc. will post -0.74 EPS for the current fiscal year.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.